Tondervik, Anne, Sletta, Havard, Klinkenberg, Geir, Emanuel, Charlotte, Powell, Lydia C., Pritchard, Manon F., Khan, Saira, Craine, Keiron M., Onsoyen, Edvar, Rye, Phil D., Wright, Chris, Thomas, David W. and Hill, Katja E. 2014. Alginate oligosaccharides inhibit fungal cell growth and potentiate the activity of anti-fungals against Candida and Aspergillus spp. PLoS ONE, e112518. 10.1371/journal.pone.0112518

Publishers page: http://dx.doi.org/10.1371/journal.pone.0112518

Citation for final published version:

Please note:
Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher’s version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.
Alginate Oligosaccharides Inhibit Fungal Cell Growth and Potentiate the Activity of Antifungals against Candida and Aspergillus spp

Anne Tøndervik¹, Håvard Sletta¹*, Geir Klinkenberg¹, Charlotte Emanuel², Lydia C. Powell², Manon F. Pritchard², Saira Khan², Kieron M. Craine², Edvar Onsøyen³, Phil D. Rye³, Chris Wright⁴, David W. Thomas², Katja E. Hii²

¹Department of Bioprocess Technology, SINTEF Materials and Chemistry, N-7465 Trondheim, Norway, ²Advanced Therapies Group, Tissue Engineering and Regenerative Dentistry, Cardiff University School of Dentistry, Cardiff, CF14 4X, United Kingdom, ³AlgiPharma AS, Industriveien 33, N-1337 Sandvika, Norway, ⁴Centre for NanoHealth, Systems and Process Engineering Centre, College of Engineering, Swansea University, Swansea, SA2 8PP, United Kingdom

Abstract
The oligosaccharide OligoG, an alginate derived from seaweed, has been shown to have anti-bacterial and anti-biofilm properties and potentiates the activity of selected antibiotics against multi-drug resistant bacteria. The ability of OligoG to perturb fungal growth and potentiate conventional antifungal agents was evaluated using a range of pathogenic fungal strains. Candida (n = 11) and Aspergillus (n = 3) spp. were tested using germ tube assays, LIVE/DEAD staining, scanning electron microscopy (SEM), atomic force microscopy (AFM) and high-throughput minimum inhibition concentration assays (MICs). In general, the strains tested showed a significant dose-dependent reduction in cell growth at ≥6% OligoG as measured by optical density (OD₆₀₀; P < 0.05). OligoG (≥0.5%) also showed a significant inhibitory effect on hyphal growth in germ tube assays, although strain-dependent variations in efficacy were observed (P < 0.05). SEM and AFM both showed that OligoG (≥2%) markedly disrupted fungal biofilm formation, both alone, and in combination with fluconazole. Cell surface roughness was also significantly increased by the combination treatment (P < 0.001). High-throughput robotic MIC screening demonstrated the potentiating effects of OligoG (2, 6, 10%) with nystatin, amphotericin B, fluconazole, miconazole, voriconazole or terbinafine with the test strains. Potentiating effects were observed for the Aspergillus strains with all six antifungal agents, with an up to 16-fold (nystatin) reduction in MIC. Similarly, all the Candida spp. showed potentiation with nystatin (up to 16-fold) and fluconazole (up to 8-fold). These findings demonstrate the antifungal properties of OligoG and suggest a potential role in the management of fungal infections and possible reduction of antifungal toxicity.

Introduction
The increase in invasive fungal infections over the last decade is a growing cause for concern as they are associated with high mortality rates [1]. The likely reasons for this increase include greater use of immunosuppressive therapy, selective pressure through broad-spectrum antibiotic use, medical and prosthetic device-related infections [2], as well as the spread of HIV/AIDS and an increasingly ageing population [1,3]. Candida albicans and Aspergillus fumigatus are the most common species associated with fungal invasive diseases, but the importance of other Candida species and filamentous fungi like Scedosporium and Fusarium [4] is becoming apparent. In addition to C. albicans, C. glabrata, C. parapsilosis, C. tropicalis and C. krusei, together account for 92% of the detected cases of candidemia [5]. In aspergillosis, after A. fumigatus, A. flavus is the most common causative species [6].

Amphotericin B has for many years been the first line of treatment for fungal infections despite its nephrotoxic side effects. Amphotericin B and polyene resistance is occasionally reported, but until now, has had limited clinical importance [4]. However, azole antifungals such as fluconazole, itraconazole and voriconazole, although effective antifungal agents, have shown development of resistance [7]; it being well-recognised among Aspergillus species in particular. Echinocandins, a newer class of antifungals which are generally well-tolerated, are considered to be a potential first line treatment for many patients due to their activity against azole-resistant strains [8,9]. In general, the clinical value of many common antifungal therapeutics is limited by toxicity, and considerable efforts are being made to reduce this toxicity in
some of the conventional antifungal drugs. For example, less toxic lipid formulations of amphotericin B have now been produced and approved for clinical use [10].

Another strategy for enhancing efficacy and reducing drug toxicity is the use of combined therapies. Several in vitro studies performed using combinations of antifungals have shown synergistic effects, demonstrating the potential of this strategy [11,12,13,14]. An alternative approach has been to potentiate the effect of antifungals through the use of different non-antibiotic compounds, such as peptides [15,16], ion-chelators [17], essential oils [18,19] or secondary metabolites of plant and microbial origin [20,21,22]. Combining antifungals with antibiotics such as colistin (an antibiotic in current use with significant toxicity issues) has also been performed using combinations of antifungals have shown synergistic effects, demonstrating the potential of this strategy [20,21,22].

The novel alginate oligomer OligoG is an oligosaccharide enriched from sodium alginate polysaccharides and composed predominantly of α-L guluronic acid (>96%), possessing only a small percentage of the β-D-mannuronic acid isomer (<4%). OligoG has recently been shown to perturb multi-drug resistant bacteria by influencing biofilm formation and reducing resistance to antibiotic treatment [24]. In the present study, we tested this alginate oligomer in combination with conventional antifungal treatment (selected polyenes, azoles and allylamines) against a panel of Aspergillus and Candida strains, to determine if this potentiation was evident against fungal pathogens.

Materials and Methods

Fungal strains, alginate oligomers and antibiotics

The strains used in this study represent both culture collection strains and clinical isolates and are shown in Table 1. The alginate oligomer, OligoG, used in the study was prepared, purified and characterized as described previously [24] and the antifungals employed were pharmaceutical grade (Sigma-Aldrich).

Preparation of freezer-stock cultures and growth characterization of the test strains

Candida strains were grown at 34°C for 48 h on Yeast Mold-agar (YM-agar, Difco). One to three fungal colonies from the plates were grown in 6 mL YM-broth at 34°C for 14 h before freezing in 6% glycerol at −80°C. Aspergillus strains were grown at 30°C for 96 h on YM-agar. Spores and aerial mycelia were then cut from the agar, suspended in 1 mL YM-broth and dispersed with glass beads (1 mm) in a mini bead-beater (2 min). Glycerol was added to a final concentration of 10% and the suspension was frozen at −80°C. Each batch of frozen stock culture was then characterized in separate growth experiments (results not shown) using Mueller-Hinton broth (MH, Lab114, LabM) and RPMI with 0.2% glucose (RPMI-1640, Sigma-Aldrich) to determine the minimum amount of inoculum giving satisfactory growth after 48 h under conditions relevant for the determination of minimum inhibitory concentration assays (MICs) as described below. This inoculum procedure was used to reduce inter-experimental variation in the bioassays. For characterization of growth in the two different media, strains were grown with static incubation in 384-well microplates (30 μL per well, Nunc 242757) and optical density (OD₆₀₀) measured between 24–96 h using a Beckman Coulter Paradigm microplate reader. Prior to OD measurements, the microplates were shaken at 1800 rpm (2.5 mm amplitude) for 2 mins.

Susceptibility testing by robotic minimum inhibitory concentration (MIC) assay

The ability of alginate oligomers to potentiate the activity of selected antifungals against the Candida and Aspergillus test strains was studied by susceptibility testing using high-throughput robotic screening (HTS) as described previously [24]. Alginate oligomers were dissolved in medium to 1.25 times the desired assay concentrations (2, 6 and 10%). Selected antifungals from different classes included: nystatin, amphotericin B (polyenes),

| Strain designation | Source |
|--------------------|--------|
| Candida albicans ATCC 90028 | Blood |
| Candida albicans CCUG 39343¹ | Human faeces |
| Candida parapsilosis ATCC 22019² | Coeliac patient |
| Candida krusei 141/03 | Pseudomembranous candidosis |
| Candida krusei 249/03(2) | Ulceration |
| Candida lusitaniae 994/01(2) | Candidosis suspension |
| Candida tropicalis 12 | Vaginal |
| Candida tropicalis 519468 | Urinary |
| Candida tropicalis 250/03 | Pseudomembranous candidosis |
| Candida tropicalis T2.2 | Oral |
| Candida glabrata ATCC 2001 | Faeces |
| Aspergillus niger CCUG 18919 (ATCC 16404)² | Blueberry |
| Aspergillus fumigatus CCUG 17460 | Unknown |
| Aspergillus flavus CCUG 28296 | Shoe sole |

¹Recommended by CLSI as reference strains for antifungal susceptibility testing.

https://doi.org/10.1371/journal.pone.0112518.t001
fluconazole, miconazole and voriconazole (azoles) and the topical antifungal, terbinafine (allylamine). The *Candida* strains were tested against nystatin, fluconazole and terbinafine, (one from each class) whilst the *Aspergillus* strains were tested against all six antifungals. Two-fold serial dilutions of antifungals were made in medium with different concentrations of OligoG, and the solutions were placed in four parallel wells in 384-well micro plates (30 µL per well). Serial dilutions were performed with a Tecan Genesis RSP 200 liquid handling workstation equipped with an 8-channel pipetting tool, using sterile disposable 200 µL barrier tips. Into each well in the 384-well assay plates 7.5 µL, of the medium inoculated with frozen stock culture of the relevant strains (described above) was added. The microplates were placed in plastic bags and incubated in a Thermo Cytomat 2 450 S robotic incubator without shaking at 34 °C. The overnight culture (10 mL) was centrifuged at 2,100 × g for 10 mins and resuspended in fresh SAB at 37 °C to attain 10^6/mL cells (OD_{530}). Bioreactors were formed in polystyrene petri dishes (60 mm × 15 mm) using 6 mL of 10^6 cells in SAB, and incubated with gentle rocking at 37 °C for 30 mins. The bioreactors were then thoroughly washed (3x) in pre-warmed media and 6 mL of fresh media and/or 2% OligoG and fluconazole (1 mg/L) added followed by incubation with gentle rocking at 37 °C for a further 90 mins. The use of this shorter bioreactor growing time was necessary to optimize AFM imaging. The bioreactors were rinsed twice with de-ionised water and dried at room temperature for 1 h before imaging with a Dimension 3100 AFM instrument (Bruker) using a scan speed of 0.4 Hz. Mean surface roughness (Ra) measurements were used to investigate the impact of the cell treatments on the morphology of the fungal cell wall by measuring a 1 μm² area at the centre of each fungal cell observed within 50 μm² tapping mode images.

**Statistical Analysis**

Statistical analysis was performed using GraphPad Prism3 (GraphPad software Inc, California, USA). A paired T-test with 95% confidence intervals was used to test the significance in the differences in growth at various OligoG-concentrations and in the mean number of cells producing hyphae following incubation with OligoG. Where the rules of a paired T-test were not obeyed, a Mann-Whitney test was performed. The non-parametric Kruskal-Wallis one-way analysis of variance was used for analysis of the surface roughness data. P<0.05 was considered significant.

**Results**

**Growth characteristics of *Candida and Aspergillus spp***

Initial studies were performed to characterize the growth of *Candida* and *Aspergillus* strains in 384-well plates in RPMI and MH. According to standardized protocols these media are recommended for antibiotic susceptibility testing in yeast and bacteria respectively [27,28]. For all strains tested, the cell mass obtained after incubation for 24–48 h (which is the recommended duration of incubation before MIC determination) in RPMI was lower than that observed in MH, as shown for *C. tropicalis* 519468 and *A. flavus* (Figure S1). The primary objective of the present study was to explore the effects of OligoG on fungal growth, either...
alone or in combination with antifungal agents. Even though MH is used mostly for bacterial susceptibility testing, we chose to use this broth for our studies since all our test strains exhibited better growth characteristics under the relevant cultivation conditions in MH. However, parallel experiments were performed in RPMI with selected strains to ensure that the effects observed were not exclusive to MH (Figure S2).

Addition of OligoG to MH reduced the growth of all the fungal strains tested in a concentration dependent manner (Figure 1). Hence, the effect was most pronounced with 10% OligoG leading to a 15–50% reduction in cell density after 48 h incubation. Growth of selected strains of Candida (n = 5) and Aspergillus (n = 3) in RPMI also showed a reduction in OD600 of 8–35% with 10% OligoG (Figure S2), showing that this effect was not media-dependent. Analysis of the growth kinetics showed that the specific growth rate ($\mu$) in MH was only slightly reduced by the addition of OligoG. Typically for A. flavus and C. tropicalis growth rates of $\mu = 0.22/t$ (without OligoG) and $\mu = 0.19–0.2/t$ (with 10% OligoG) were observed.

Germ Tube Assay

Light microscopy images of the germ tube assay revealed that OligoG had a pronounced effect on the hyphal growth of C. albicans CCUG 39343 (Figure 2A) demonstrating a reduced number of cells producing hyphae following treatment with OligoG. The actual concentration of OligoG required to produce an effect however, was species-dependent. The percentage number of cells with hyphal growth decreased significantly using ≥0.5% OligoG for C. albicans 39343 and C. tropicalis 519468, and ≥6% OligoG for C. albicans 90028 when compared to the control (Figure 2B, P<0.05). The pH of the Candida cultures in serum remained between pH 7.2 and 7.5 throughout, showing that the observed effects were not pH related.

Effect of OligoG on C. tropicalis biofilms using fluorescence microscopy, scanning electron microscopy (SEM) and atomic force microscopy (AFM)

LIVE/DEAD staining (Figure 3), SEM (Figure 4) and AFM images (Figure 5) all revealed that C. tropicalis 519468 biofilms grown in the presence of 2% OligoG showed distinct differences in biofilm structure compared to the control. OligoG treatment caused increased cell and hyphal death (LIVE/DEAD staining), which in turn resulted in a more ‘open’ and less densely formed biofilm matrix (SEM). The SEM images also appeared to confirm the germ tube assay findings that C. tropicalis grown in the presence of OligoG produced less hyphae. Fluconazole used at concentrations equivalent to ‘below’, ‘at’ and ‘above’ the MIC value in conjunction with 2% OligoG revealed a potentiation effect on the inhibition of C. tropicalis (Figure 4). The combined treatment (at every fluconazole dose) produced a more porous/open structure of the biofilm (with less biomass and more water channels) when compared to fluconazole treatment alone.

AFM imaging (Figure 5), showed less marked alterations in the structure of the OligoG-treated biofilms than that observed with LIVE/DEAD and SEM imaging and reflected the use of less mature biofilms (2 h), which were necessary to optimise the AFM imaging (compared to 24 h in the other imaging experiments). Nevertheless, there were clear morphological changes in response to treatment, with either more rounded cells (after OligoG treatment), or more flattened cells (after fluconazole treatment). However, the combination treatment resulted in reduced cell and hyphal growth, while also showing the most distinctive morphological changes, with cells appearing both flattened, and “wrinkled” when compared to fluconazole or OligoG treatment alone (Figure 5). There was no significant difference in surface roughness (Ra) measurements between the control and 2% OligoG treated samples (P>0.05). However, there was a significant increase in Ra for both the combined fluconazole and 2% OligoG, and fluconazole alone treatments (P<0.001) compared to the control (Figure S3).

Figure 1. Effect of increasing concentrations of OligoG (0, 2, 6, and 10%) on cell densities. Cultivation in Mueller-Hinton broth for 48 h at 34 °C for various Candida and Aspergillus species. Error bars represent standard deviation from the mean (n≥4). (*, data not significantly different from control results; P>0.05).

doi:10.1371/journal.pone.0112518.g001
**Figure 2. Germ tube assays.** (A) Light microscopy images of *Candida albicans* (CCUG 39343) cells grown with/without the presence of OligoG. (Scale bar is 100 μm). (B) Percentage of *Candida* cells producing hyphae for four different strains grown for 2 hours in the presence of OligoG (0, 0.2, 0.5, 2, 6 and 10%). *Candida glabrata* as a non-hyphae producer was the negative control. * indicates significantly different from the control, *(P<0.05). doi:10.1371/journal.pone.0112518.g002

**Figure 3. LIVE/DEAD fluorescence imaging of *Candida tropicalis* 519468.** Biofilms were grown for 24 h at 37°C showing vital live cells (green) versus dead cells (red). (A) Untreated control. (B) 2% OligoG. doi:10.1371/journal.pone.0112518.g003
The effect of OligoG on potentiation of antifungals against *Candida* and *Aspergillus* spp

OligoG was able to potentiate the effect of selected antifungal agents commonly used to treat fungal infections (Table 2 and Table 3). For the three *Aspergillus* strains, a reduction in MIC was found for all antifungal agents tested. This decrease was similar for all antifungals (≤4-fold) except nystatin, for which the greatest decrease was observed (up to 16-fold). All the *Candida* strains showed potentiation with nystatin (up to 16-fold with *C. parapsilosis*) and fluconazole (up to 8-fold with four strains). In addition, the majority of the *Candida* test strains appeared resistant to terbinafine (MIC > 32 mg/L), with the exception of *C. lusitaniae*, *C. parapsilosis* and *C. krusei*. Of all the *Candida* spp., only *C. lusitaniae* showed potentiation with terbinafine (4-fold).

**Discussion**

The aim of this study was to perform a screen to determine both the direct effect of OligoG on a range of *Candida* and *Aspergillus* species and, indirectly, its ability to potentiate the activity of...
### Table 2. MIC of antifungals alone and with increasing concentrations of OligoG (2, 6, 10%) for a range of *Aspergillus* spp.

| Isolate                  | Nystatin | Amphotericin B | Miconazole | Voriconazole | Terbinafine |
|--------------------------|----------|----------------|------------|--------------|-------------|
|                          | MIC (mg/L) at indicated OligoG concn (%) |               |            |              |             |
|                          | 0        | 2              | 6          | 10           | 0           | 2           | 6          | 10           | 0           | 2           | 6          | 10          |
| *A. niger* CCUG 18919    | 0.188    | 0.188          | 0.094      | 0.047        | <0.03       | <0.03       | <0.03      | <0.03       | <0.03       | 0.25        | 0.25       | 0.25       | 0.25        |
| *A. fumigatus* CCUG 17460| 0.75     | 0.375          | 0.375      | 0.188        | <0.03       | <0.03       | <0.03      | <0.03       | <0.03       | 0.125       | 0.125      | 0.125      | 0.125       |
| *A. flavus* CCUG 28296   | 0.75     | 0.375          | 0.375      | 0.188        | <0.03       | <0.03       | <0.03      | <0.03       | <0.03       | 0.125       | 0.125      | 0.125      | 0.125       |

Bold numbers indicate a Fractional Inhibitory Concentration Index (FICI) < 0.5; indicative of synergy [25].

doi:10.1371/journal.pone.0112518.t002

### Table 3. MIC of antifungals alone and with increasing concentrations of OligoG (2, 6, 10%) for a range of *Candida* spp.

| Isolate                  | Nystatin | Fluconazole* | Terbinafine |
|--------------------------|----------|--------------|-------------|
|                          | MIC (mg/L) at indicated OligoG concn (%) |               |             |
|                          | 0        | 2            | 6          | 10           | 0           | 2           | 6          | 10 |
| *C. albicans* CCUG 39343 | 0.25     | 0.25         | 0.25       | 0.25         | >32         | <0.13       | <0.13      | 8 |
| *C. parapsilosis* ATCC 22019T | 0.5      | 0.5          | 0.5        | 0.5          | >32         | <0.13       | <0.13      | 8 |
| *C. krusei* 141/03       | 0.13     | 0.13         | 0.13       | 0.13         | >32         | <0.13       | <0.13      | 8 |
| *C. lusitaniae* 994/01(2) | 0.13     | 0.13         | 0.13       | 0.13         | >32         | <0.13       | <0.13      | 8 |
| *C. tropicalis* 12       | 0.13     | 0.13         | 0.13       | 0.13         | >32         | <0.13       | <0.13      | 8 |
| *C. tropicalis* 519468   | 0.25     | 0.25         | 0.25       | 0.25         | >32         | <0.13       | <0.13      | 8 |
| *C. tropicalis* 250/03   | 0.25     | 0.25         | 0.25       | 0.25         | >32         | <0.13       | <0.13      | 8 |
| *C. tropicalis* T2.2     | 0.25     | 0.25         | 0.25       | 0.25         | >32         | <0.13       | <0.13      | 8 |

*MIC values of fluconazole for *C. tropicalis* strains (519468 and T2.2) were determined at 36 h.

Bold numbers indicate a Fractional Inhibitory Concentration Index (FICI) < 0.5; indicative of synergy [25].

doi:10.1371/journal.pone.0112518.t003
conventional antifungal therapies. The potentiation effects of OligoG were investigated with antifungal agents from different chemical classes; with polyenes, azoles and allylamines being employed in these assays. The antifungals which were studied included those agents most commonly prescribed for human and veterinary use. From a mechanistic and novel therapy perspective, it was of interest to determine whether any potentiation effects of antifungals seen with OligoG were similar for the entire selected range of Candida and Aspergillus spp., whilst recognising that all antifungals tested were not currently deemed clinically relevant for the test strains that were utilized.

This in vitro study clearly demonstrates that the novel alginate oligomer, OligoG, was able to modulate both fungal growth and fungal biofilm formation. Moreover, OligoG was also shown to potentiate the activity of a range of antifungal agents, giving up to a 16-fold reduction in MIC values. Given the toxicity of many antifungals, these findings represent a potential clinical benefit in the management of fungal infections. This is supported by similar observations for OligoG in potentiating the activity of antibiotics against multi-drug resistant gram-negative bacteria [24].

Resistance to antifungal agents is commonplace. The majority of the Candida strains tested in this study were resistant to terbinafine. A large variation in susceptibility towards terbinafine among different clinical Candida isolates has previously been described [29] and resistance has been linked to overexpression of the efflux pump genes CDR1 and CDR2 from the ABC transporter gene family [30]. The polyenes such as amphotericin B bind to ergosterol, the major sterol in the fungal cell membrane, and form pores, thereby causing membrane damage. In contrast, azoles target sterol biosynthesis by inhibiting the sterol 14α-demethylase, the product of the ERG11 gene. Resistance to fluconazole has been associated with point mutations and increased ERG11 expression or over-expression of efflux-pump genes CDR1, CDR2 and MDRI [31]. Importantly, resistance of Candida spp. to classic triazole antifungal agents is increasing. The MIC testing of the Candida strains demonstrated potentiation (up to 8-fold) of antifungal azoles.

Several efflux pumps of A. fumigatus have also been identified. However, their involvement in drug resistance is less well established and little is known about how their expression is regulated [31]. Recently, a deletion mutant for the transcription factor SrbA in A. fumigatus was found to confer susceptibility to fluconazole, which is not normally active against this pathogen [32]. Unsurprisingly therefore, there was little effect of fluconazole on the Aspergillus strains tested; two being resistant (MIC>128) while the A. flavus strain showed only a low level of potentiation (2-fold) with OligoG.

Although there is some controversy surrounding the pathogenicity of Aspergillus spp. and the decision to treat infections caused by this genera in some indications (i.e. lung infection in cystic fibrosis patients) these arguments are strongly influenced by the immune status of the host, clinical signs of infection and patient microbiology [33]. Overuse of antifungal agents, antifungal resistance and drug costs are all problems for these patients. The ability of OligoG to reduce the MIC and thereby potentiate the effect of antifungal agents in vivo, may provide wider treatment options in the management of resistant fungal lung infections, which are an increasing problem with triazoles.

In addition to the potentiation activity of OligoG, it clearly showed antifungal activity when used alone. The modification of biofilm structure, together with growth inhibition, and hyphae effects were evident in all of the imaging techniques (conventional light and fluorescence microscopy, SEM and AFM) employed in this study. These methods demonstrated that the altered growth characteristics were associated with distinct morphological changes, which subsequently resulted in biofilm disruption, increased cell death, and reduced hyphal formation. In previous studies, inhibition of bacterial growth by OligoG was associated with marked decreases in cell motility as seen in bacterial swarming assays [24,34]. These earlier observations support the current findings that OligoG has a direct effect on the invasive, hyphal growth phase of Candida spp.

AFM is increasingly being used to study the effect of antimicrobial agents on the cell surface [24,34]. Recently using AFM, we showed strong binding of OligoG to the cell surface of the pathogenic bacteria Pseudomonas aeruginosa, which remained bound even after hydrodynamic shear [35]. Although similar antimicrobial effects were observed with fungal pathogens, there was no apparent similarity in the binding of OligoG to the fungal cell wall. Nevertheless, morphological changes were clearly evident. While these studies are not directly comparable (organisms were in different growth states, planktonic versus biofilm), it would suggest that different mechanisms of action are involved in the antimicrobial effects observed in bacterial and fungal pathogens. This is unsurprising given the contrasting differences in cell wall structure and charge. The fungal cell wall is principally composed of three main components: β-glucans (microfibrillar polymers of glucose; ~60%), chitin (~2%) and mannoproteins (~39%) [36]. As a means of combating potential cell lysis, the composition of the cell wall can be altered using a 'compensatory mechanism' which is activated in response to changes in their immediate environment such as cell wall perturbing agents or mutations. This allows the cell wall to be remodelled [37] and can result in an increased level of chitin [38]. The response to such cues can effectively direct changes in fungal growth, cell wall mass, ultrastructure, plasticity and adhesion, enzyme production and pathogenicity [39]. While it is not known whether OligoG induces this kind of remodeling effect, it is a charged molecule and so could influence, or be influenced by, molecular changes in the cell wall.

The observation that OligoG inhibits hyphae formation is particularly relevant in light of recent co-infection studies with Staphylococcus aureus and C. albicans [40]. Both organisms are commonly isolated bloodstream pathogens, often found as co-infecting agents. They are also both capable of forming biofilms, and show increasing evidence of antimicrobial resistance, thereby representing a significant and growing problem in the management of polymicrobial infections. Specific binding of S. aureus to the hyphae of co-cultured C. albicans (via Als3p binding) has been shown to enable tissue infiltration and subsequent deep tissue infection by S. aureus [40]. Undoubtedly, antimicrobials capable of targeting both bacteria and yeasts, such as OligoG, have a distinct advantage for such polymicrobial infections.

Although a precise molecular mechanism of action has yet to be established, it is thought that the synergistic and antimicrobial activity of OligoG in disrupting the biofilm matrix/architecture could potentially permit: a) better access for antimicrobial agents and/or host innate defenses to biofilm-embedded organisms and, b) previously dormant (drug-tolerant) cells to move into a more drug-susceptible phase of growth. The current in vitro observations would appear to support some of these hypotheses, but will need to be tested with appropriate in vivo models.

Clearly further studies are needed to determine the precise molecular mechanisms of OligoG in microbial infections. Notwithstanding, the antifungal effects and potentiating activity observed in this study represent considerable promise for the clinical utility of OligoG in the treatment and management of fungal infection and reduction of antifungal toxicity in clinical practice. Phase I and IIa studies have demonstrated that OligoG is
safe for human use, in vivo testing having shown no intolerance to inhaled doses of up to 540 mg/day (https://ClinicalTrials.gov, NCT00970346 and NCT01465329, EudraCT, 2009-009330-33). OligoG is currently being developed for topical wound application, and studies are ongoing for the use of OligoG as an inhaled therapy for cystic fibrosis.

Supporting Information

Figure S1 Growth of (A) C. tropicalis 519468 and (B) A. falcus at 34°C in Mueller-Hinton broth (open squares) and RPMI (solid squares). (TIF)

Figure S2 Effect of increasing concentrations of OligoG (0%, 2%, 6%, and 10%) on cell densities after cultivation in RPMI broth for 48 h at 34°C for various Candida and Aspergillus species. Error bars represent standard deviation from the mean (n≥4). (*P < 0.05). (TIF)

References

1. Lass-Florl C (2009) The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 52: 197–205.
2. Ramage G, Martinez JP, Lopez-Ribot JL (2006) Candida biofilms on implanted biomaterials: a clinically significant problem. FEBS Yeast Res 6: 979–986.
3. Silva S, Negri M, Henriques M, Oliveira R, Williams DW, et al. (2012) Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. FEMS Microbiol Rev 36: 298–305.
4. Alcazar-Fuoli L, Mellado E (2014) Current status of antifungal resistance and its impact on clinical practice. Br J Haematol 166: 471–484.
5. Guimaraes J (2014) Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect 20: 5–10.
6. Walsh TJ, Gamalotos MN (2013) Treatment of fungal disease in the setting of neutropenia. Hematology-American Society of Hematology Education Program: 423–427.
7. Aperis G, Myriounis N, Spanakis EK, Mylonakis E (2006) Developments in the impact of essential oils against natural and synthetic iron chelators alone and in combination with azole and fluconazole. Phytother Res 20: 58–61.
8. Giordani R, Reghi P, Kalsoisut J, Mikail C, Abou L, et al. (2004) Antifungal effect of various essential oils against Candida albicans. Potentialization of antifungal action of amphotericin B by essential oil from Thymus vulgaris. Phytother Res 18: 990–993.
9. Giordani R, Reghi P, Kalsoisut J, Portugal H (2006) Potentialization of antifungal action of amphotericin B by essential oil from Cinnamomum cassia. Phytother Res 20: 58–61.
10. Ali I, Sharma P, Suri KA, Satti NK, Dutt P, et al. (2011) In vitro antifungal activities of amphotericin B in combination with actosolade, a phenethanol glycoside from Calosperum oppositifolium. J Med Microbiol 60: 1326–1336.
11. Veras HNH, dos Santos JMF, dos Santos ACB, Fernandes CN, Matias EFF, et al. (2011) Comparative evaluation of antifungal and antibiotic modifying activity of quercetin and isoeugenol in vitro. Gastroenterol Nutraceutical Res 9: 25–29.
12. Fokula T, Haasegyn V, Sakate Y, Tsomoda H, Ouma S (2008) Citramimides, new potentiators of antifungal miconazole activity, produced by Penicilium sp FKI-1938. J Antibiot 61: 550–555.
13. Veras HNH, dos Santos IJM, dos Santos ACB, Fernandes CN, Matias EFF, et al. (2012) Synergy of the antibiotic colistin with echinocandin antifungals in Candida species. J Antimicrob Chemother 68: 1283–1296.
14. Khan S, Tondervik A, Sletta H, Klinkenberg G, Emanuel C, et al. (2012) Overcoming drug resistance with algal extract antiglaucoma in vitro. J Antimicrob Chemother 67: 1–11.
15. Odds FC (2003) Synergy, anatase, and what the chequerboard puts between them. J Antimicrob Chemother 52: 1–1.
16. Murillo GA, Newport G, Lan CY, Habelitz S, Dungan J, et al. (2005) Genome-wide transcription profiling of the early phase of biofilm formation by Candida albicans. Eukaryot Cell 4: 1562–1573.
17. Arendrup MC, Cuenca-Estrella M, Lass-Flores C, Hope W, Eucast A (2012) EUCAST technical note on the EUCAST definitive document ED7.2: method for the determination of broth dilution minimum inhibitory concentration of antifungal agents for yeasts EDf 7.2 (EUCAST-AFST). Clinical Microbiology and Infection 18: E246–E247.
18. Institute CaLS (2005) Performance standards for antimicrobial susceptibility testing; 15th informational supplement, M100-S15. Wayne PA.
19. Rieder NS, Wagner S, Leitner I (1998) In vitro antifungal assessment of derivatives against cutaneous isolates of Candida albicans and other pathogenic yeasts. Antimicrob Agents Chemother 42: 1057–1061.
20. Odds FC (2009) In Candida albicans, resistance to fluconazole and other azoles is linked to MAT locus homozygosity and nucleotide sequence type clustering. J Antimicrob Chemother 64: 1091–1101.
21. Morschhauser J (2010) Regulation of multidrug resistance in pathogenic fungi. Fungal Genet Biol 47: 94–106.
22. Willger SD, Patukamkouk S, Kim KH, Burritt JB, Grahl N, et al. (2008) A sterol-regulatory element binding protein is required for cell polarity, hyphopodia adaptation, azole drug resistance, and virulence in Aspergillus fumigatus. Plos Pathog 4.
23. De Paauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, et al. (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46: 1013–1821.
24. Powell LC, Sowedan A, Khan S, Wright CJ, Hawkins K, et al. (2013) The effect of various essential oils against Candida albicans and other pathogenic yeasts. Antimicrob Agents Chemother 57: 1821–1827.
25. Powell LC, Sowedan A, Khan S, Wright CJ, Hawkins K, et al. (2013) The effect of various essential oils against Candida albicans and other pathogenic yeasts. Antimicrob Agents Chemother 57: 1821–1827.
26. Alva I, Sharma P, Suri KA, Satti NK, Dutt P, et al. (2011) In vitro antifungal activities of amphotericin B in combination with actosolade, a phenethanol glycoside from Calosperum oppositifolium. J Med Microbiol 60: 1326–1336.
27. Veras HNH, dos Santos JMF, dos Santos ACB, Fernandes CN, Matias EFF, et al. (2011) Comparative evaluation of antifungal and antibiotic modifying activity of quercetin and isoeugenol in vitro. Gastroenterol Nutraceutical Res 9: 25–29.
28. Fokula T, Haasegyn V, Sakate Y, Tsomoda H, Ouma S (2008) Citramimides, new potentiators of antifungal miconazole activity, produced by Penicilium sp FKI-1938. J Antibiot 61: 550–555.
29. Khan S, Tondervik A, Sletta H, Klinkenberg G, Emanuel C, et al. (2012) Overcoming drug resistance with algal extract antiglaucoma in vitro. J Antimicrob Chemother 67: 1–11.
30. Odds FC (2003) Synergy, anatase, and what the chequerboard puts between them. J Antimicrob Chemother 52: 1–1.
31. Morschhauser J (2010) Regulation of multidrug resistance in pathogenic fungi. Fungal Genet Biol 47: 94–106.
32. Willger SD, Patukamkouk S, Kim KH, Burritt JB, Grahl N, et al. (2008) A sterol-regulatory element binding protein is required for cell polarity, hyphopodia adaptation, azole drug resistance, and virulence in Aspergillus fumigatus. Plos Pathog 4.
33. De Paauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, et al. (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46: 1013–1821.
34. Powell LC, Sowedan A, Khan S, Wright CJ, Hawkins K, et al. (2013) The effect of various essential oils against Candida albicans and other pathogenic yeasts. Antimicrob Agents Chemother 57: 1821–1827.
37. Klis FM, Mol P, Helinck K, Brefl S (2002) Dynamics of cell wall structure in Saccharomyces cerevisiae. FEMS Microbiol Rev 26: 239–256.

38. Lagorce A, Le Berre-Anton V, Aguilar-Uscanga B, Martin-Yken H, Dagens-manskaia A, et al. (2002) Involvement of GFA1, which encodes glutamine-fructose-6-phosphate amidotransferase, in the activation of the chitin synthesis pathway in response to cell-wall defects in Saccharomyces cerevisiae. Eur J Biochem 269: 1697–1707.

39. Ene IV, Adya AK, Wehmeier S, Brand AG, MacCallum DM, et al. (2012) Host carbon sources modulate cell wall architecture, drug resistance and virulence in a fungal pathogen. Cell Microbiol 14: 1319–1335.

40. Peters BM, Ovchinnikova ES, Krom BP, Schlecht LM, Zhou H, et al. (2012) Staphylococcus aureus adherence to Candida albicans hyphae is mediated by the hyphal adhesin AlcIp. Microbiology (SGM) 158: 2975–2986.